KRAS and colorectal carcinoma: Notably, the mutation of valine (V) to glutamic acid (E) at residue 600 on BRAF (BRAFV600E), a kinase downstream of KRAS, is found in microsatellite stable CRC patients and contributes to poor clinical outcomes, including the resistance to anti-epidermal growth factor receptor (EGFR) therapy [16].